Questcor Evaluating Development Strategies Following Acthar “Not Approvable” Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Competing firm Ovation tells “The Pink Sheet” DAILY it plans to submit its anticonvulsant vigabatrin for infantile spasms later this year.